SILVER SPRING
High-dose Spinraza regimen approved for spinal muscular atrophy
- Sponsor
- Biogen Inc. $BIIB
- Drug
- Spinraza · nusinersen
- Indication
- spinal muscular atrophy
FDA approved a high-dose regimen of Spinraza (nusinersen) for spinal muscular atrophy.
What this means
Spinraza is an injected drug that helps treat spinal muscular atrophy by boosting a protein needed for muscle movement. The FDA just approved a higher-dose version of Spinraza for patients with this rare nerve-muscle disease. This could give doctors more flexibility in dosing for patients who may need stronger treatment to manage their symptoms.
Drug Watch — recent news on Spinraza
- England to start screening newborns for rare disease SMA - pharmaphorum
- My Spinraza Journey & Spinal Muscular Atrophy Update | Victortheinspiration On Camera Talks Brett Goldstein (oUYBRilVZ9) - Mshale
- Biogen launches SMA campaign “Ready for More\" to highlight next-gen Spinraza patients - PharmaLive
- Muscle ultrasound helps assess SMA in children treated with approved drug - SMA News Today
- Spinraza from Biogen Inc. - established SMA therapy faces biosimilar pressure - ad-hoc-news.de
Sponsor Watch — recent news on Biogen Inc.
- Slate Medicines Appoints Mark W. Hahn to Board of Directors
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- 3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
- Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
- Biogen Appoints Michael J. Parini as Chief Legal Officer